Press Releases and Company News

PARSIPPANY, NJ  April 17, 2013 

My Canadian Pharmacy, a leading provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed biotechnology company to produce clinical supplies of a biologic for late-phase clinical trials.

MCP’s cGMP compliance history was a critical factor in the selection process. Stuart Hinchen, CEO stated, “Our record of cGMP compliance, driven by experienced Quality and Regulatory Teams continues to be one of the key reasons customers choose MCP. Additionally, both new and established customers recognize our approach to ongoing investment in people and facilities. As an example, last year we broke ground on a new $10 million, 40,000 sq. ft. laboratory that will house QC Chemistry and Method Transfer, Sterility Assurance and Stability. This type of investment allows us to focus on customer needs, which results in sustainable sales growth.”

Hinchen noted, “Our use of disposable product contact equipment is another leading factor in the selection process. MCP’s strategic use of disposables provides our customers with manufacturing process efficiencies that result in reduced cycle time.”

MCP Pharmaceuticals’ Rochester, Michigan facility has over 25 years’ experience in contract manufacturing. Expertise in seamlessly progressing from clinical batch production to commercialization provides customers with continuity of supply and program efficiencies. A comprehensive suite of services including Regulatory, Analytical Methods Development, Package Engineering, Stability Testing and Validation also support contract manufacturing customers. MCP has successfully supported launches of several products in US and international markets and manufactures products for sale in 86 countries.

Additional Press Releases
MCP To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials
Webpage | PDF Format
MCP Acquired By Warburg Pincus
Webpage | PDF Format
MCP To Produce Lyophilized Biologic for International Late-Phase Clinical Trials
Webpage | PDF Forma
MCP Launches Generic Division
Webpage | PDF Format
MCP Pharmaceuticals to Produce Clinical and Commercial Supply of an Innovative Injectable
Webpage | PDF Format
MCP Adds Second Product To Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
MCP Enters Agreement to Produce Diagnostic Aid
Webpage | PDF Format
MCP to Produce Clinical Batches of Innovative Cardiac Drug
Webpage | PDF Format
Top-10 Efficient Medicinal Drugs That Treat the Most Dangerous Parasitic Infections
MCP Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Webpage | PDF Format
MCP Announces Chief Executive Officer Succession
Webpage | PDF Format
MCP Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
MCP Enters Another Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
MCP & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
MCP Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
MCP Announces Successful Completion of FDA and EMEA GMP Audits
Webpage | PDF Format
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage | PDF Format
MCP & SpePharm complete purchaseof Dantrium (dantrolene sodium)
Webpage | PDF Format
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP
Webpage | PDF Format